One more clinical study regarding COVID-19 infection has been completed, the chairman of the German-Azerbaijani Society of Radiology and Neuroradiology, Doctor of Medical Sciences at the University Hospital Cologne, Azerbaijani scientist Nuran Abdullayev told Report.
According to him, the new study was published in “The Lancet” magazine.
The Azerbaijani scientist said that the clinical study shows positive impacts of budesonide drug, commonly used to treat asthma, on the COVID-19 patients.
Abdullayev noted that the following results have been obtained from treatment with budesonide twice a day for 7 days:
- Period of general treatment was reduced
- Those taking Budesonide drug had lower temperature than those who were not treated with that drug
- After two weeks, their persistent symptoms were less, and therefore it is expected to prevent the symptoms of "Long COVID"
- Patients taking Budesonide used antipyretics for a short period
- Taking Budesonide reduces the risk of hospitalization by about 90%. This was observed 3 days after the appearance of symptoms.
- The mild side effects are about 7%.
“Inhalation of budesonide twice a day reduces the risk of serious medical intervention in hospital and shortens the recovery period. Thus, COVID-19 patients can use this drug with the scientific ground,” Abdullayev said.